{"created":"2022-02-22T03:31:35.933717+00:00","id":2015898,"links":{},"metadata":{"_buckets":{"deposit":"52d4f6d7-52ad-48f5-92ac-6995d9e1b304"},"_deposit":{"id":"2015898","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2015898"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02015898","sets":["1642838163960:1642838198944:1642838199408:1642838203782","1642838403551:1642838412624"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"[原著］ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^<tax>抗体の臨床的意義","subitem_1551255648112":"ja"},{"subitem_1551255647225":"Clinical Significances of sIL-2R, IAP and p401^tax Aitibody in ATL Patients and HTLV- I Carriers","subitem_1551255648112":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"増田, 昌人","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"大城, 一郁","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"下地, 忠夫","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"高須, 信行","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"Masuda, Masato","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ohshiro, Kazuiku","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shimoji, Tadao","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takasu, Nobuyuki","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_1522650717957":"ja","subitem_1522651041219":"琉球医学会"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"ATL"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"HTLV- I"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"sIL-2R"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"IAP"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"p40^<tax> antibody"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"We have assessed the usefulness of using soluble interleukin-2 receptor (sIL-2R), immunosuppressive acidic protein (IAP), and p40^<tax> antibody for making out the subtypes of adult T-cell leukemia (ATL) and for differentiating among ATL patients, human T-cell leukemia virus type I (HTLV- I ) carriers, and normal individuals. We measured these parameters in 51 patients with ATL (21 acute, 3 lymphoma, 18 chronic, and 9 smoldering), 52 HTLV- I carriers, and 30 normal controls. The serum sIL-2R level was $15.0 \\pm 23.6$ ( $mean \\pm standard$  deviation) ×10^3 U/ml in the ATL patients ($22.7 \\pm 26.8$ ×10^3 U/ml in acute and lymphoma ATL,  $2.47 \\pm 1.79 $ ×10^3 U/ml in chronic ATL, $1.17  \\pm 1.13$ ×103 U/ml in smoldering ATL), $0.62 \\pm 0.22$ ×10^3 U/ml in the HTLV-I carriers, and $0.17 \\pm 0.14$ X10^3 U/ml in the normal controls. Serum sIL-2R levels were significantly higher in the ATL patients than in the HTLV- I carriers and normal controls. Serum sIL-2R levels were also significantly higher in the HTLV- I carriers than in the normal controls. In addition, serum sIL-2R levels were significantly higher in acute and lymphoma ATL than in chronic and smoldering ATL. The serum IAP level was  $784 \\pm 346$  $ \\mu $g/ml in acute and lymphoma ATL, which was significantly higher than the levels of $453 \\pm 211$ $ \\mu $g/ml in chronic and smoldering ATL, $389 \\pm 96$ $ \\mu $g/ml in HTLV- I carriers, and $348 \\pm 88$ $ \\mu $g/ml in normal controls. p40^<tax> antibody was positive in 37 of the 51 ATL patients (16 of the 24 acute and lymphoma ATL patients and 21 of the 27 chronic and smoldering ATL patients) and in 28 of the 52 HTLV- I carriers, but was not detected in the normal controls. We conclude that sIL-2R is useful for disting-uishing the different subtypes of ATL and for separating ATL patients, HTLV- I carriers, and normal individuals. IAP is useful to distinguish patients with the acute and lymphoma ATL from those with chronic and smoldering ATL, HTLV- I carriers, and normal individuals. In addition, p40^<tax> antibody is useful to distinguish normal individuals from HTLV- I carriers and ATL patients.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"ja","subitem_1522300316516":"琉球医学会"},{"subitem_1522300295150":"en","subitem_1522300316516":"Ryukyu Medical Association"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"jpn"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"ISSN","subitem_1522646572813":"1346888X"},{"subitem_1522646500366":"ISSN","subitem_1522646572813":"0289-1530"},{"subitem_1522646500366":"NCID","subitem_1522646572813":"AN10369445"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_1522650068558":"ja","subitem_1522650091861":"琉球医学会誌 = Ryukyu Medical Journal"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1994","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"55","bibliographicPageStart":"49","bibliographicVolumeNumber":"14"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"VoR","subitem_1600292170262":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"v14p49.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2015898/files/v14p49.pdf"},"version_id":"d3fdf109-57cc-4c89-92ed-65cdd45fce37"}]},"item_title":"[原著］ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^<tax>抗体の臨床的意義","item_type_id":"15","owner":"1","path":["1642838203782","1642838412624"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-07-02"},"publish_date":"2010-07-02","publish_status":"0","recid":"2015898","relation_version_is_last":true,"title":["[原著］ATL患者およびHTLV-IキャリアにおけるsIL-2R、IAP およびp40^<tax>抗体の臨床的意義"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-10-31T07:46:34.963538+00:00"}